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Abstract 
We describe the development of automated workflows that support computed -aided drug discovery 
(CADD) and  molecular dynamics (MD) simulat ions and are included as part of the National 
Biomedical Computation Resource (NBCR). The main workflow components include: file -
management tasks, ligand force field parameterizat ion, receptor-ligand molecu lar dynamics (MD) 
simulations, job submission, serial and parallel execution, and monitoring on relevant high-
performance computing (HPC) resources, receptor structural clustering, virtual screening (VS), and 
statistical analyses of the VS results. The workflows aim to standardize simulation and analysis and 
promote best practices within the molecu lar simulation and CADD communit ies. Each component is 
developed as a stand-alone workflow, which should allow for easy integration into larger frameworks 
built suiting user needs, while remaining intuitive and easy to extend. 
 
Keywords: Scientific workflows, molecular simulation, ligand parameterization, small molecule docking, 
structural clustering, big data reduction, web services, relaxed complex scheme 
1 Introduction 
Using computer simulat ion as an aid in drug d iscovery is not novel, yet the field is somet imes still 
considered in  its infancy, an  opinion that may be due to the relatively complicated processes involved 
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and the lack of community-wide standard procedures. Furthermore, the continuous development of 
new computer arch itectures  and software parallelization can result in large amounts of data, upwards 
of 1 terabyte for single computer-aided drug discovery (CADD) projects. Perhaps as a result of th is 
enabling technology, it is common for practitioners to spend more time analyzing the data than 
generating it. W ith this in mind, our aim is the development of robust, reusable workflows for 
simulation preparation, job execution, and analysis that simplify best practices and help the 
community make the most of their rich data sets. 
To develop automated, standardized protocols, we employ Kepler [1], a scientific workflow 
framework. Kepler is a  free, open-source software suite designed for analyzing and modeling 
scientific data. The Kepler software simplifies the creation of executable models (scientific 
workflows), even by researchers with little  programming background [2]. Additionally, it  is a  platform 
for users to share and reuse data, workflows, and components for a wide range of scientific and 
engineering applicat ions [3, 4]. Kepler has powerful support to handle new cyber infrastructure 
demands (e.g., intelligently handling/brokering access to Extreme Science and Engineering Discovery 
Environment (XSEDE) and other simulation-relevant platforms), and it is particu larly well suited to 
handle workflows that cross scales. The flexibility of Kepler makes it an ideal environment for sharing 
methods among scientists, thus increasing reproducibility and accessibility. Kepler also provides a 
provenance framework (e.g. data lineage and the processing history of workflow runs) that collects 
informat ion, which can be v iewed through a molecular modelers’ virtual notebook [5]. Th is latter 
feature also makes it possible to detail methods, software names and versions, resource specifications 
and computational cost in literature reports, in a straight-forward manner similar to the standardized 
reporting that exists for small-molecule crystal structures [6]. 
2 The relaxed complex scheme – main components 
Previously, we developed a CADD pipeline schematic called the relaxed complex scheme (RCS), 
[7], an end-to-end CADD experiment that incorporates receptor flexibility into virtual screening (VS) 
by utilizing molecular dynamics (MD) simulat ions. As summarized schematically in Figure 1, the 
RCS facilitates all steps of VS, including: (1) generating compound libraries, (2) generating and 
selecting receptor structures, (3) performing virtual screens, (4) reevaluating  and characterizing 
docked poses, and (5) sharing virtual-screening results. While not illustrated in Figure 1, workflow 
results lend themselves to statistical validation, an extension discussed in section 3.7  
Building on our earlier RCS efforts that were designed with a specific task in -mind, we are 
developing individual, stand-alone workflows that are modular and reusable. Collectively, they form a 
“toolkit” of powerful methods that can be assembled to address a range of challenging VS problems. 
In particular, to incorporate protein flexib ility into rational d rug discovery and design, we  are 
constructing a class of workflows to automate the setup, execution, and evaluation of molecular 
dynamics simulations. The workflows can be assembled in novel ways, creating environments where 
system-specific MD analysis can be meaningfully conducted, providing extended utility beyond 
CADD and the RCS. Each  Kepler-based reusable workflow module is called  an “actor” and is built 
primarily on an open-source software platform, or on software that is free to academic groups. The 
near universal accessibility of the workflows should translate to broad dissemination and use, allowing 
researchers to handle the challenges inherent in (big) data more effectively. 
To prevent each workflow from becoming a “black box”, where appropriate, we are focused on 
including metrics or analytics that allow the user to judge the quality of the output an d make key 
scientific decisions. As an example, we  will focus on providing applicat ions that make conducting and 
reporting novel MD analyses standard, routine and reproducible [8].  
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We furthermore plan  to build workflows that support data sharing and transportation through cloud 
and other distributed platforms that facilitate usage of high-speed networks. The combination of these 
functionalities will provide a simple but powerfu l way to create and share customizable reports among 
members of large scientific collaborations. 
3 CADD workflow – main actors 
3.1 File management for ligand parameterization 
For organizational purpose, we developed a Kepler composite actor that takes a list of PDB files, 
which is a standardized file format containing structural informat ion regarding molecules, and creates 
subdirectories using the PDB names. The PDB files are then copied to the corresponding 
subdirectories. Subsequently, generated data associated with each PDB is stored consistently, 
providing better informat ion control. While this actor is a s mall actor, it provides proper file 
management, a crucial component of CADD. 
3.2 Ligand Parameterization 
An MD simulat ion of a protein-ligand complex requires development of ligand force field 
parameters. Parameterization can be cumbersome and is commonly a multi -step process handled by a 
series of user scripts. To streamline this process, we developed a ligand parameterization composite 
actor͒ (Figure 2), that follows the “gold standard” Amber protocol, using Antechamber [9] and 
Gaussian [10]. Th is actor has been parallelized using Kepler to distribute the workload and can 
therefore easily accept a large number of ligands as inputs. For each ligand, Antechamber assigns 
force field atom͒ types, while Gaussian performs a min imization before calculating the electrostatic 
 
Figure 1: General workflow for ensemble-based VS experiment. Blue arrows indicate size of data sets (i.e. 
increasing or decreasing) at each step; * denotes emerging methods that have not yet been tested. (AMD: 
accelerated molecular dynamics, GB MD: generalized Born molecular dynamics, RMSD: root -mean-square-
deviation, ZINC – ZINC Is Not Commercial,  ACD: Available Chemical Database, NCI: National Cancer 
Institute, MM-PB(GB)SA: Molecular Mechanics – Poisson-Boltzmann (Generalized Born) Surface Area). 
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potential (ESP), both at the HF/6-31G* level. Atomic partial charges are then assigned to reproduce 
the ESP using the RESP protocol [11]. The actor will read  a directory of ligand PDB files and process 
them simultaneously. The PDB files will be moved into corresponding subdirectories to ensure that all 
output files are well organized along with their inputs when performing the calculations in parallel.  
These files and directories are then grouped together for the parameterizat ion step as inputs, and lastly 
a distributor actor splits the task into smaller jobs that are executed in parallel.  This composite 
actor͒ subsequently outputs the required FRCMOD and PREPC files containing the force field 
parameters, which are reusable and easily shared. 
3.3 Receptor-ligand molecular dynamics simulations 
The binding of a ligand to a receptor is a dynamic event. Small molecule compounds can assume 
many different binding poses, and receptor flexibility may change due to ligand binding. Therefore, it 
is important to consider the dynamic behavior of both ligands and receptors during CADD. One 
commonly  applied method to describe the receptor-ligand dynamics is MD simulat ions of the 
complex. The steps to prepare an MD simulat ion can be routine but lengthy, especially when 
considering many different receptor-ligand complexes. To standardized and automate the process, we 
have developed a Kepler composite actor that simplifies the preparation of MD simulat ions of these 
complexes (see Figure 3). This actor takes the outputs generated from the ligand parameterization 
actor as the inputs. Furthermore, it requires a receptor PDB file in order to start the workflow. Once 
started, the job will run through three major components, described below, that collectively  prepare 
and run an MD simulation of the user’s system. 
Component I – Vina: Given PDB files of a ligand and a receptor, this module prepares the 
prerequisite files and docks the ligand into the receptor using Autodock Vina. The result is a PDB file 
that describes the “docked pose” of the ligand, or the conformation of the ligand when bound to the 
receptor. 
Component II –  PDB Modification: By  concatenating the docked-pose PDB file to the PDB file of 
the receptor, component II first creates a merged ligand-receptor complex. Next , the receptor-ligand 
complex is assigned Amber force field parameters, and the topology and coordinate files required for 
MD are generated. Prior to simulating system dynamics, a  restrained minimization  is typically  carried 
out to remove steric conflicts, which can cause MD programs to crash. In a final step, component II 
prepares the restraint files required during minimization. 
 
 
Figure 2: Kepler composite actor for the parameterization of small molecule ligands for MD  
 
 
Figure 3: Layout of the Receptor-ligand molecular dynamic simulations actor.  
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Component III – Remote Login: This module of the composite actor prepares configuration files 
for MD simulation with NAMD [12] and writes submission scripts for running min imization, 
equilibrat ion and production jobs on the XSEDE resource Stampede, located at the Texas Advanced 
Computing Center (see Figure 4). Future developments will enable users to employ alternate HPC 
resources. In order to take advantage of parallel computing, the files required fo r MD simulation that 
were generated in earlier steps must be moved to the HPC platform. Component III performs th is 
operation, moving the prerequisite files to a user specified directory on a remote HPC resource. Once 
the files are transferred, component III executes and monitors min imization jobs on the HPC resource, 
generates the files necessary for a restrained MD equilibration, performs the restrained MD 
equilibration, and finally executes the production MD simulation. 
3.4 Receptor structural clustering 
An MD simulat ion yields a “trajectory,” or a set of coordinates that represent the conformational 
states of the protein with or without a bound ligand as it evolves through time typically starting from 
an experimentally determined structure. With modern HPC resources, these trajectories can consist of 
thousands or even millions of conformat ions, which translates into giga- or terabytes of data, making 
structural analysis challenging. Fortunately, meaningful dataset reduction methods have been devised 
that extract representative conformations, or structures. These structures, are generally d ifferent than 
the experimentally  determined structure(s), and the active sites display alternative conformations 
referred to as cryptic binding pockets [13-15], and can be exploited in subsequent VS.  
Considering the size o f contemporary  MD datasets, an effective, integrated platform for studying 
protein dynamics will require workflow actors  that leverage data reduction software in a single, 
cohesive, user-friendly framework. To that end, we developed a modular set of actors that process MD 
trajectories by GROMOS cluster analysis [16], a  method that categorizes protein  conformations based 
on structural similarity (see Figure 5). In the first processing step, the Trajectories Listing composite 
actor utilizes cpptraj, implemented in AmberTools, to concatenate short discontinuous trajectories into 
one long continuous trajectory. The PDB Creator and PDB Modifier actors then convert the input 
trajectory file to the PDB format required by Gromacs [17], and also strips solvent molecules and 
correct for periodic boundary conditions. The Atom Selection actor p icks out the active site residues a 
user has predefined and creates a PDB file containing all the atom indices of the selected residues. The 
 
Figure 4: Breakdown of the remote login composite actor of the receptor-ligand dynamic simulation actor. 
 
Figure 5: Gromos receptor structural clustering actor.  
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files are then sent to the public NBCR Opal server, which aligns each trajectory conformation to a 
common reference and clusters the data using the Gromacs. We are planning to extend this workflow 
to include options for alternative clustering strategies. 
3.5 Receptor and ligand preparation for docking 
Docking programs, such as the widely used AutoDock [18] and AutoDock Vina (Vina) [19], 
provide scientists an estimate of the free energy change that occurs when a ligand binds to a receptor. 
Both AutoDock and Vina require PDBQT files that des cribe the coordinates, atomic part ial charges, 
and AutoDock atom types of the ligand and the receptor. To streamline the conversion procedure, we 
have developed an actor that converts a receptor PDB to PDBQT file, which can be used by both 
AutoDock and Vina (see Figure 6). The actor uses the publicly available NBCR Opal server to 
perform the conversion, while Kepler monitors job scheduling and returns the output PDBQT file to 
the user’s local machine. In the future, this actor will be extended to convert PDB to PDBQT for the 
ligand files as well. 
3.6 Ensemble based virtual screening 
As previously stated, proteins are dynamic, and static crystal structures can offer a poor account of 
protein flexibility, part icularly when it is pronounced. In a drug  discovery context, th is flexibility is 
manifested in the observance of so-called cryptic binding pockets [13-15], or ligand binding sites that 
are absent in a crystal structure but are present during an MD simulat ion. To incorporate these 
potential binding sites during VS, it is important to include an ensemble of protein receptor structures 
that models the flexib ility of a receptor in solution. Here, we describe an actor that screens large ligand 
sets against different receptor conformations using Vina [19] (see Figure 7). Users supply a directory 
of receptor PDB files, a directory of ligand PDB files and grid information. Receptor PDB and ligand 
 
Figure 6: Receptor preparation for VS actor. 
 
Figure 7: Virtual screening actor.  
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PDB files are converted to Vina specific PDBQT files. Every ligand is matched with each receptor 
once in the “Mix&Match” module, which organizes the large number of files generated in th is 
protocol. The combinations are sent to Vina one by one for VS. Then, users have the option to either 
run VS locally or on the NBCR Opal server. This implementation has been made using the bioKepler 
extension [20]. Moreover, this actor carries out provenance and is able to output information regarding 
receptors, ligands, runtime and machines used for each run (data not shown). 
3.7 Virtual screening performance statistics  
During VS, s mall molecu les are assigned a score e.g. during small molecule docking, the score is a 
predicted binding affin ity of a small molecu le to a receptor target, and those compounds predicted to 
bind more favorably receive a higher rank and are more likely to be experimentally assayed.  
Performing VS using an ensemble o f protein conformat ions may benefit the discovery effort, but it 
is also computationally demanding and scales linearly with the number of conformations. To improve 
computational efficiency, statistical methods can be used to select the ensemble that does the best job 
of separating known the binders from the known non-binders in a small, experimentally characterized 
compound database. By carefully selecting the best performing ensemble, this protocol has the 
potential to reduce the computational expense of screening a much larger database of uncharacterized 
compounds. 
 We have developed an actor (see Figure 8) that incorporates the experimental status of a 
compound, i.e. binder or non-binder, the docking score of the compound in  each receptor ensemble 
member, and returns the ensemble best able to discriminate known binders from known non-binders. 
Although there are various VS performance metrics available in the literature [21, 22], the area under 
the curve (AUC) of the Receiver Operating Characteristic (ROC) plot [23] is one of the most popular 
performance evaluation metrics and is used for our workflow. Part of the AUC’s appeal is how easily 
it is interpreted. It represents the probability that a randomly selected binder will have a h igher rank 
than a randomly selected non-binder [24, 25]. Consistent with this interpretation, an AUC value of 0.5 
indicates the VS protocol performs  randomly, while a value of 1 indicates the protocol ranks all of the 
binders ahead of all of the non-binders. 
In practice, ensemble selection is complicated by the need to evaluate all possible combinations of 
receptor conformations, a combinatorial process described by the binomial coefficient. The workflow 
utilizes a series of Matlab [26] scripts to monitor performance of all possible ensembles of 
conformat ions. The scripts requires a comma-separated CSV file, containing ligand identification 
numbers, e.g. compound IDs in a database, a compound classifier, i.e . a 0 or 1, which labels non-
binders and binders, respectively, and the remaining co lumns contain the docking scores for each 
receptor conformation. The scripts return the AUC value for all possible ensembles of receptor 
conformat ions, as well as the 95% confidence intervals, and p-values, which provide indications of the 
performance reliability and the statistical significance of the performance of each ensemble. 
The calculations in Matlab are designed to utilize the Parallel Computing Toolbox in Matlab 
(parfor loops), although if the separate license required to use the toolbox is not available, the behavior 
 
Figure 8: VS statistical performance actor utilizing Matlab 
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will default to standard loop iteration. The parallel option is highly recommended particularly for a 
large number of receptor structures, as these calculations otherwise become very time consuming. 
4 Integrated web-services 
The complexity of scientific applicat ions needed in CADD often requires access to HPC resources. 
To ensure tasks are completed expediently, scalable and transparent support of distributed computing 
resources available on both HPC platforms and in the cloud is required of each Kepler workflow 
module. To meet this requirement, we use the Opal toolkit [27], which  provides Scientific Software as 
a Serv ice (SaaS) using standard and simple web interfaces. For example, scientific applications 
executed by the workflows are wrapped as SOAP-based web services that allow for programmatic and 
web-based application access, which is useful for a wide variety of applications. The programmat ic 
capability allows transparent access of different workflow components, while the web -based service 
access provides a large number of NBCR applications to our affiliates and collaborators.  
Using integrated web-services for scientific applications also aids our objective to develop a 
modular environment of interchangeable, customizable modules that can be used to create complex 
scientific workflows. As SaaS providers, we handle software installation configuration and upgrade 
transparently at the cyber-infrastructure level. With infrastructure complexit ies replaced by an easy-to-
use interface, the full power of the modular workflow environment can be easily applied to pressing 
scientific problems.  
The scientific applications, wrapped as Opal web services [28], can read ily be deployed across 
distributed computing environments to accelerate completion of the scalable computations within the 
CADD framework. It is easy to access the scientific applications through the Opal web server, which 
provides a stable, reliable infrastructure for CADD and molecular simulat ions that can accommodate 
large throughput in an extensible, reproducible and reusable manner. This approach will allow flexib le 
community resource sharing and, by providing the framework to incorporate ideas from a broad 
community of users, it will promote convergence toward a set of standardized best practices. 
5 Workflow Dissemination 
CADD workflows, in  addition to other NBCR workflow products, are being made available 
though the NBCR website and GitHub [29]. We have enabled the NBCR workflows site to be 
searched and filtered easily though keywords describing the workflows’ application, actors, program 
dependency, and other relevant terms, enabling the user to select the appropriate workflow for their 
needs. Upon selecting a desired workflow the user is taken to the workflow documentation and 
download options. The workflows will be distributed through GitHub to provide transparent version 
control. The user may  either download the workflow itself, requiring a local installation of Kepler and 
dependent programs, or download the workflow as part of a Rock’s Rolls [30] containing dependent 
programs. The Rock’s Rolls  facilitate the utilization of workflows in HPC environments. 
6 Conclusions 
We have developed a series of modular actors that can be integrated into a larger CADD 
framework, or be used as stand-alone tools. The modules described here are have successfully been 
deployed on a number of different projects and are being optimized based on user feedback. These 
modules demonstrate the usability of Kepler scientific workflows in CADD with the aim to 
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standardize simulation and analysis, and to promote best practices within the molecular simulat ion and 
CADD communit ies. The workflows demonstrate usability in terms of file -management tasks, 
molecular simulation including ligand force field  parameterization and management of job submission 
and monitoring on relevant HPC resources, as well as VS elements such as receptor structural 
clustering, docking and statistical analyses of the VS results. The modules developed here were partly 
intended for specific-use cases and will in the future be subdivided into smaller modules to avoid 
redundancy, and to make them amenable to incorporate into other framework uses.  
Through our work, we have identified some novel Kepler capabilit ies that would be useful for the 
workflows in our science domain. A Kepler feature to allow for easier stitching together of several 
modules into a larger framework using a GUI framework would be helpful for more novice users. A 
particular function of this feature is for Kepler to check and match module output to subsequent 
module input requirements in the larger framework, and flag errors at the transitions, which can later 
be handled by the users in the design phase. The user can then quickly address any file format 
requirements, either by pulling in another module between the two causing the conflict, or manually 
provide/specify missing parameters. Furthermore, the current implementation fo r assembling several 
modules into a larger framework can be challenging when each module has its own PN or SDF 
director, as Kepler does not currently allow the PN actor to exist inside another PN or SDF director.  
 The current models are available for download on the NBCR website and have been integrated 
with NBCR web-services. Our lab is currently developing novel Kepler workflows designed for 
automation and standardizing of common tasks in CADD and molecu lar simulation. Additionally, we 
are developing domain specific interfaces for all NBCR workflows. These interfaces will integrate key 
visualizat ion software, workflow modification, workflow execution management, and electronic lab 
book functions further optimizing the CADD process. We will solicit user feedback and use it to guide 
our efforts, to  strengthening an ecosystem that encourages development and distribution of workflows 
with the simulation and CADD communities. 
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